GlaxoSmithKline’s first-of-a-kind malaria vaccine Mosquirix will undergo real-world pilot studies in three African countries selected by the World Health Organization.
Starting next year, the pilots will enroll babies aged 5 to 17 months to test the vaccine’s efficacy in the real-world setting, and to study whether delivering four doses is feasible in healthcare-strapped, but malaria-heavy, sub-Saharan areas.
“Information gathered in the pilot program will help us make decisions on the wider use of this vaccine,” Matshidiso Moeti, WHO regional director for Africa, said in the release. “Combined with existing malaria interventions, such a vaccine would have the potential to save tens of thousands of lives in Africa.”
Check out the full article here: GlaxoSmithKline’s malaria shot set for WHO pilot test in Ghana, Kenya and Malawi
Welcome to Clinical Research Trends, a new blog dedicated to providing breaking news on clinical trial recruitment, patient engagement, new technology and noteworthy trends. With this blog, we are working to provide clinical research organizations, sponsors and leading service providers with critical news and industry updates on a regular basis. If you want to learn more about the latest trends in clinical trial recruitment and drug development, you’ve come to the right place.